Comparing different doses of tenecteplase for treating acute ischemic stroke
Official title: A Multicentre, Prospective, Randomized, Open Label, Blinded-endpoint Trial to Optimize the Use of Intravenous Tenecteplase in Participants With Acute Ischemic Stroke (ACT-GLOBAL THROMBOLYSIS (ACT WHEN-001) Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL) NCT06352632
Run by University of Calgary · NCT06320431 · Data updated 2026-11-12
This study is testing whether a standard dose or a lower dose of a medication called tenecteplase can help people who have had an acute ischemic stroke recover better and stay safe.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | University of Calgary Academic / other |
| Locations | 24 sites (Sydney, Barangaroo and 23 other locations) |
| Status | Recruiting |
| Started | September 26, 2024 |
| Main results expected | September 30, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06320431 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with disabling acute ischemic stroke who present within 4.5 hours of symptom onset and may benefit from intravenous thrombolysis.
✕Probably not a fit
Patients with absolute contraindications for intravenous thrombolysis or those experiencing minor strokes with non-disabling symptoms may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the effectiveness of standard-dose versus low-dose intravenous tenecteplase in patients with acute ischemic stroke. It employs a randomized, controlled, open-label design with blinded endpoint assessment, enrolling up to 4,000 patients who present to hospitals within 4.5 hours of symptom onset. Participants will be followed for 90 days to assess outcomes related to stroke recovery and safety. The trial also investigates the use of tenecteplase in conjunction with endovascular thrombectomy when necessary.
Why it matters
Potential benefit: If successful, this study could lead to optimized dosing of tenecteplase, improving recovery outcomes for patients with acute ischemic stroke.
How similar studies have gone: Previous studies have shown promising results with tenecteplase, indicating its potential efficacy compared to alteplase, making this approach both relevant and timely.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All patients with disabling AIS presenting within 4.5 hours of symptom onset or last known well who may benefit from intravenous thrombolysis (IVT) with tenecteplase. Patients potentially eligible for IVT with conditions described as relative contraindications in national guidelines where physician discretion is recommended are eligible. Patients who received a DOAC, and those planned for emergency EVT are eligible. 2. Consent process completed as per national laws and regulation and the applicable ethics committee requirements. Exclusion Criteria: 1. Any absolute contraindication for IV thrombolysis per current national guidelines. Examples include those who are actively bleeding, had recent intracranial surgery, head trauma, intracranial or subarachnoid hemorrhage, or a bleeding diathesis. 2. Minor stroke patients with non-disabling symptoms.
Where it's running
-
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia Recruiting -
Monash University (Box Hill)
Melbourne, Victoria, Australia Recruiting -
University of Calgary
Calgary, Alberta, Canada Recruiting -
University of Alberta
Edmonton, A, Canada Recruiting -
University of British Columbia
Vancouver, British Columbia, Canada Recruiting -
University of Manitoba - Winnipeg Health Science Centre
Winnipeg, Manitoba, Canada Recruiting
Show 18 more locations
-
Health Sciences North Horizon Sante-Nord
Greater Sudbury, Ontario, Canada Recruiting -
McMaster University Hamilton Health Sciences Centre
Hamilton, Ontario, Canada Recruiting -
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada Recruiting -
St. Michael's Hospital
Toronto, Ontario, Canada Recruiting -
Sunnybrook Health Science Centre
Toronto, Ontario, Canada Recruiting -
Queen Elizabeth Hospital (PEI)
Charlottetown, Prince Edward Island, Canada Recruiting -
Royal University Hospital
Saskatoon, Saskatchewan, Canada Recruiting -
The George Institute for Global Health
Sydney, Barangaroo, Australia Not yet recruiting -
Medicine Hat Regional Hospital
Medicine Hat, Alberta, Canada Not yet recruiting -
Red Deer Regional Hospital
Red Deer, Alberta, Canada Not yet recruiting -
Kelowna Regional Hospital
Kelowna, British Columbia, Canada Not yet recruiting -
Royal Columbian Hospital
New Westminster, British Columbia, Canada Not yet recruiting -
Brandon Regional Hospital
Brandon, Manitoba, Canada Not yet recruiting -
Queen Elizabeth II Health Science Center (Halifax)
Halifax, Nova Scotia, Canada Not yet recruiting -
Kingston General Hospital
Kingston, Ontario, Canada Not yet recruiting -
Lawson Health Research Institute- London
London, Ontario, Canada Not yet recruiting -
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada Not yet recruiting -
CIUSSS de l'Estrie - CHUS Fleurimont Hôpital (Sherbrooke)
Sherbrooke, Quebec, Canada Not yet recruiting
Study contacts
- Principal investigator: Bijoy K Menon, MD, MSc — University of Calgary
- Study coordinator: Bijoy K Menon, MD, MSc
- Email: bkmmenon@ucalgary.ca
- Phone: 4039448107
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-stop approach for rapid start of endovascular clot removal
This trial will test whether taking eligible adults with suspected large- or medium-vessel ischemic stroke straight to the angiography suite for imaging and treatment gets clot-removal therapy started faster and improves outcomes.
-
Effectiveness of a new neurorehabilitation technology for stroke recovery
This study is testing a new rehabilitation technology that uses robots and virtual reality to see if it can help stroke patients recover better than regular therapy.
-
Music therapy after stroke
This trial tests whether adding music therapy to standard care helps stroke patients sleep better and feel less anxious or depressed while in the hospital.
-
Mobilisation After Endovascular Stroke Treatment
This study checks whether moving around 12 hours after endovascular stroke treatment is as safe as moving around 24 hours for people with an acute ischemic stroke.
-
Endovascular therapy plus standard care vs standard care alone for distal and medium vessel strokes
In people with acute ischemic stroke due to distal or medium vessel blockages, this study tests whether adding endovascular treatment to the usual medical care helps improve outcomes compared with medical care alone.
-
Inter-Limb Transfer after Acute Stroke
This study tests whether practicing motor skills with the affected arm helps improve movement in the other arm after an acute stroke.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.